Systemic Anti-Cancer Therapy Regimen Library
GYN GTD - metHOTREXATe [low risk]
Treatment Overview
Continuous for 3 cycles beyond normal ß-hCG.
Cycle 1 (and all further cycles) - 14 days
If it is not feasible to administer metHOTREXate on day 7, it may be administered on day 8 with foliNIc acid administered on day 9.
Cycle details
Cycle 1 (and all further cycles) - 14 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| metHOTREXATe * | 50 mg flat dosing | intramuscular injection | 1, 3, 5, 7 |
|
| foliNIc acid (as calcium folinate) * | 15 mg flat dosing | oral administration | 2, 4, 6, 8 |
If it is not feasible to administer metHOTREXate on day 7, it may be administered on day 8 with foliNIc acid administered on day 9.
Full details
Cycle 1 (and all further cycles) - 14 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| metHOTREXATe * | 50 mg flat dosing | intramuscular injection |
Day: 2
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| foliNIc acid (as calcium folinate) * | 15 mg flat dosing | oral administration |
Instructions:
Take 24 hours after metHOTREXATe on an empty stomach - one hour before OR two hours after food. |
Day: 3
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| metHOTREXATe * | 50 mg flat dosing | intramuscular injection |
Day: 4
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| foliNIc acid (as calcium folinate) * | 15 mg flat dosing | oral administration |
Instructions:
Take 24 hours after metHOTREXATe on an empty stomach - one hour before OR two hours after food. |
Day: 5
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| metHOTREXATe * | 50 mg flat dosing | intramuscular injection |
Day: 6
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| foliNIc acid (as calcium folinate) * | 15 mg flat dosing | oral administration |
Instructions:
Take 24 hours after metHOTREXATe on an empty stomach - one hour before OR two hours after food. |
Day: 7
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| metHOTREXATe * | 50 mg flat dosing | intramuscular injection |
Instructions:
If it is not feasible to administer metHOTREXate on day 7, it may be administered on day 8 with foliNIc acid administered on day 9. |
Day: 8
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| foliNIc acid (as calcium folinate) * | 15 mg flat dosing | oral administration |
Instructions:
Take 24 hours after metHOTREXATe on an empty stomach - one hour before OR two hours after food. If metHOTREXate was administered on day 8 instead of day 7, take foliNIc on day 9, 24 hours after meTHOTREXATe. |
Supportive Care Factors
| Factor | Value |
|---|---|
| Emetogenicity: | Minimal |
References
Greater Metropolitan Clinical Taskforce NSW Department of Health. 2009. "Best Clinical Practice: Gynaecological Cancer Guidelines."
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.